



**Contact:**

David Waldman or Natalya Rudman  
Crescendo Communications Europe Sp. z o.o.  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)

Dom Maklerski WDM S.A.  
Email: [us@wdmcapital.com](mailto:us@wdmcapital.com)  
Tel: (+48 71) 79 11 555

**Milestone Medical Inc. Receives CE Mark Approval for Epidural Injection System**

**LIVINGSTON, NJ, September 18, 2014 -- Milestone Medical Inc. (WAR: MMD)**, today announced it has received CE Mark regulatory approval to market and sell its epidural injection system in Europe. The CompuFlo™ Epidural Computer Controlled Anesthesia System (CompuFlo™ Epidural Model 6000) is intended for the verification of needle tip placement in the lumbar epidural space in patients over age of 18 and the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their Health Care Provider.

Leonard Osser, Chief Executive Officer of Milestone Medical stated, "CE approval for our epidural instrument follows the recent CE approval of our intra-articular instrument. CE approval is an important achievement and further validation of our technology as we move towards commercial sale of the epidural injection system. Our next steps involve securing strategic partners to distribute our products in Europe, as we have already done in the U.S. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago. Millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection. Epidurals represent a multi-billion dollar global market and we believe our technology can transform these injections from an art to a science."

Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular injection systems is now complete and the Company is currently pursuing regulatory approval for both injection systems in the U.S. and European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

C:\Users\lkaunitz\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\OORSNICA\MMD CE approval epidural - FINAL.docx

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*